The study found that mutations in six specific genes such as Cyclin D1 [CCND1], Cyclin D3 [CCND3], SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin Subfamily B Member 1 [SMARCB1], Fanconi Anemia Complementation Group G [FANCG], Cyclin-Dependent Kinase Inhibitor 2A/2B [CDKN2A/B], and MutS Homolog 6 [MSH6] were significantly associated with shorter progression-free survival (PFS) in canine patients [64]. This evidence concerns the gene CCND3 and Fanconi anemia complementation group G.